Caplin Point Laboratories Limited
Caplin Steriles, a subsidiary of Caplin Point Laboratories, secured final USFDA approval for its Foscarnet Sodium Injection ANDA. This approval allows the company to launch a generic version of a drug with US sales of approximately $15 million.
May 14 2026 19:05:00
Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Caplin Point Laboratories' subsidiary, Caplin Steriles Limited, secured USFDA final approval for Foscarnet Sodium Injection (6000 mg/250 mL), a generic antiviral drug. This approval opens up access to the US market for a product with approximately $15 million in annual sales.
May 14 2026 19:05:00
Caplin Point Laboratories Limited
Caplin Point declared an interim dividend of Rs. 4 per equity share for FY26. The record date is May 30, 2026, and payment will be made by June 13, 2026.
May 14 2026 18:05:00
Caplin Point Laboratories Ltd - 524742 - Corporate Action-Board approves Dividend
Caplin Point declared an interim dividend of ₹4.00 per equity share (200% on ₹2 face value) for FY26. The record date for eligibility is May 30, 2026, impacting shareholders for the fiscal year ending March 31, 2026.
May 14 2026 13:05:00
Caplin Point Laboratories Ltd - 524742 - Board Meeting Outcome for For Meeting Held On May 14, 2026
Caplin Point Laboratories board declared an interim dividend of ₹4.00 per share and approved Q4 and FY26 consolidated results. For Q4 FY26, total revenue rose 19% YoY to ₹628.52 cr, and net profit increased 19% YoY to ₹172.88 cr. The full-year FY26 saw total revenue grow 13.2% YoY to ₹2,302.73 cr and net profit rise 20.1% YoY to ₹649.73 cr, with a record date for dividend set for May 30, 2026.
May 14 2026 13:05:00
Caplin Point Laboratories Limited
Caplin Point Laboratories will hold a board meeting on May 14, 2026. The agenda includes considering annual financial results for FY26 and the declaration of an interim dividend, if any, along with fixing its record date.
May 07 2026 16:05:00
Caplin Point Laboratories Limited
CAPLIN POINT LABORATORIES LIMITED board will convene on May 14, 2026, to review and approve the audited annual standalone and consolidated financial results for the financial year ending March 2026. Additionally, the board will consider declaring an interim dividend for shareholders.
May 07 2026 16:05:00
Caplin Point Laboratories Ltd - 524742 - Board Meeting Intimation for Approval Of Financial Results And Declaration Of Interim Dividend, If Any, Approved By The Board.
Caplin Point Laboratories has scheduled a board meeting for May 14, 2026. The agenda includes the consideration and approval of the annual audited financial results for FY2025-26 and the potential declaration of an interim dividend, along with fixing its record date.
May 07 2026 16:05:00
Caplin Point Laboratories Limited
Caplin Point's subsidiary, Caplin Steriles Limited, has received final USFDA approval for its Abbreviated New Drug Application (ANDA) for Calcium Gluconate Injection USP. This approval opens access to the US market for a drug with annual sales of approximately $71 million.
May 05 2026 12:05:00
Read More